Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Read-GeneWAR:RDG 80 Days Payable is 813.99 as of Mar. 2026, which is 94% above its 10-year median of 419.36. GuruFocus rates WAR:RDG with a GF Score™ of 80/100 and a GF Value™ of zł6.37 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 701 Biotechnology companies, Read-Gene ranks better than 75.61% on this metric.
Read-Gene's average Accounts Payable for the
three
months ended in Mar. 2026 was zł1.57 Mil. Read-Gene's Cost of Goods Sold for the
three
months ended in Mar. 2026 was zł0.18 Mil.
Hence, Read-Gene's Days Payable for the
three
months ended in Mar. 2026 was 813.99.
The historical rank and industry rank for Read-Gene's Days Payable or its related term are showing as below:
WAR:RDG'
s Days Payable Range Over the Past 10 Years
Min: 242.81 Med: 419.36 Max: 549.49
Current: 401.09
During the past 13 years, Read-Gene's highest Days Payable was 549.49. The lowest was 242.81. And the median was 419.36.
WAR:RDG's Days Payable is ranked better than 75.61% of 701
companies
in the Biotechnology industry
Industry Median: 113.36
vs WAR:RDG: 401.09
Read-Gene's Days Payable
increased
from Mar. 2025 (254.97) to Mar. 2026 (813.99).
It may suggest that Read-Genedelayed paying its suppliers.
Read-Gene Days Payable Related Terms
Read-Gene Days Payable Historical Data
* Premium members only.
The historical data trend for Read-Gene's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:RDG vs VRTX, REGN, RVMD: Days Payable Comparison
For the Biotechnology subindustry, Read-Gene's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Read-Gene Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Read-Gene's Days Payable distribution charts can be found below:
* The bar in red indicates where Read-Gene's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Read-Gene's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Read-Gene (WAR:RDG) has a Days Payable of 813.99 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Read-Gene and its competitors. This is 94% above median its historical median of 419.36. Over the past decade, Read-Gene's Days Payable has ranged from 242.81 to 549.49. According to the industry distribution chart, Read-Gene ranks #171 out of 701 companies in the Biotechnology industry, placing it in the top 24.4%.
Is Read-Gene's Days Payable too high?
Read-Gene's current Days Payable of 813.99 is 94% above median its 10-year median of 419.36. Over the past 10 years, this metric has ranged from a low of 242.81 to a high of 549.49. The Biotechnology industry median Days Payable is 113.36. Read-Gene's value of 813.99 is 618.1% above this industry median. Based on the distribution chart, Read-Gene ranks #171 out of 701 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Read-Gene has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Read-Gene's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Read-Gene ranks #171 out of 701 companies for Days Payable. This places Read-Gene in the top 24% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.36. Read-Gene's value of 813.99 is 618.1% above this benchmark. Historically, Read-Gene's own Days Payable has ranged from 242.81 to 549.49 over the past decade. While the company's 10-year median is 419.36 vs. the industry median of 113.36, Read-Gene has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.36, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Read-Gene's current Days Payable of 813.99 is 618.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Read-Gene and its competitors. For the Biotechnology industry, the median Days Payable is 113.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Read-Gene's current Days Payable is 813.99, which is 94% above median its own 10-year median of 419.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Read-Gene stock overvalued right now?
Based on GuruFocus' analysis, Read-Gene (WAR:RDG) is currently considered Modestly Undervalued. The stock's GF Value™ is zł6.37, compared to a current price of zł4.86 — trading 23.7% below its estimated fair value. The current Days Payable is 813.99, which is 94% above median its 10-year median of 419.36 and 618.1% above the Biotechnology industry median of 113.36. Read-Gene's overall GF Score™ is 80/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Read-Gene (WAR:RDG), the current Days Payable is 813.99 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Read-Gene (WAR:RDG) Overvalued in 2026?
Based on GuruFocus' analysis, Read-Gene stock appears to be undervalued.
The current stock price of zł4.86 is trading 23.7% below its estimated GF Value™ of zł6.37.
GuruFocus considers Read-Gene to be Modestly Undervalued.
Key valuation signals for WAR:RDG:
Days Payable: 813.99 (94% above median its 10-year median of 419.36)
GF Value™: zł6.37 vs. price of zł4.86 (23.7% below fair value)
Industry Position: 618.1% above the Biotechnology median (#171 of 701)
No single metric tells the full story. See the WAR:RDG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Read-Gene SA treats each patient individually based on genetic tests. The company's segments include chemoprevention, clinical trials and genetic tests. It also engaged in developing technologies to commercialize methods to detect, prevent and treat malignant tumours.
80GF Score
Get the complete analysis for WAR:RDG
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:RDG has been successfully added to your 
